WHAT IS CLAIMED IS:

1. A compound represented by Formula (I)

5

(I)

or a pharmaceutically acceptable salt, or N-oxide, thereof, wherein

10 R¹ is

- (d) hydrogen,
- (e) C₁-C₆-alkyl,
- (f) halogen;

 $15 R^2$ is

- (g) hydrogen,
- (h) C_1 - C_6 -alkyl, optionally substituted with one or more of halogen, -OH, or aryl,
- (i) cycloalkyl,
- (j) CF₃,
- 20 (k) aryl, optionally substituted with one or more of halogen or alkyl,
 - (1) heteroaryl, optionally substituted with one or more of alkyl or halogen;

$$\begin{cases} \sqrt{q(H_2C)} NR^c & \begin{cases} \sqrt{(CH_2)q} NR^c \\ \end{cases} & \text{and} \end{cases}$$

R^c is selected from hydrogen and C₁₋₄alkyl, wherein alkyl is optionally substituted with one or more of halogen or -OH;

- n and m are independently 0, 1, 2, 3 or 4, provided that n + m = 2, 3 or 4; q is 1 or 2; and
 - R⁴ is hydrogen or halogen.
- 2. The compound of Claim 1, or a pharmaceutically acceptable salt, or an Noxide thereof, wherein

 R^2 is optionally substituted C_1 - C_6 -alkyl.

3. The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

R² is cycloalkyl.

4. The compound of Claim 1, or a pharmaceutically acceptable salt, or an N20 oxide thereof, wherein

R² is CF₃.

5. The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

R² is optionally substituted aryl.

6. The compound of Claim 1, or a pharmaceutically acceptable salt, or an N30 oxide thereof, wherein

R² is optionally substituted heteroaryl.

7. The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

$$R^3$$
 is $\{CH_2\}_n$
 $(CH_2)_m$

8. The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

$$R^3$$
 is R^{c}

10

9. The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

$$R^3$$
 is $\{CH_2)q$

15

5

10. The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

$$R^3$$
 is $q(H_2C)$ NR^c

20

11. The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

$$R^3$$
 is $\{CH_2)q$ NR^c

12. The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

$$\mathbb{R}^3$$
 is \mathbb{R}^3

5

13. The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

R³ is piperidinyl.

10

14. The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

 R^3 is [(C₁₋₄) alkyl]piperidinyl.

15

15. The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

R³ is piperidin-4-yl.

20

16. The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

 R^3 is [(C₁₋₄) alkyl]piperidin-4-yl.

25

17. The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

 ${\bf R}^3$ is 1-methylpiperidinyl.

30

18. The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

R³ is 1-methylpiperidin-4-yl.

19. The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

R³ is 1-(3-hydroxypropyl)-4-piperidinyl.

- 20. The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein
- 10 R³ is 1-(3-hydroxyethyl)-4-piperidinyl.
 - 21. A compound represented by Formula (II)

15

5

or a pharmaceutically acceptable salt, or N-oxide, thereof, wherein

- 20 Het is heteroaryl, optionally substituted with one or more of amino, alkyl or halogen; and R^1 and R^3 each is as defined in Claim 1.
- 22. The compound of Claim 21, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

Het is pyridyl.

23. The compound of Claim 21, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

Het is pyridazinyl.

24. The compound of Claim 21, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

Het is triazinyl.

5

10

15

25. The compound of Claim 21, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

Het is thiazolyl.

26. The compound of Claim 21, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

Het is isothiazolyl.

27. A compound represented by

F N N N N N N N N N N N N N N N N N N N	
N N N N N N N N N N N N N N N N N N N	N N N N N N N N N N N N N N N N N N N
F N N N N N N N N N N N N N N N N N N N	N N N N N N N N N N N N N N N N N N N

WO 2005/060571 PCT/US2004/040617

or a pharmaceutically acceptable salt, or an N-oxide thereof.

10

15

- 28. A method for controlling coccidiosis in poultry which comprises

 administering to said poultry a therapeutically effective amount, or a prophylactically effective amount, of a compound of Claim 1.
 - 29. A method for controlling coccidiosis in poultry which comprises administering to said poultry a therapeutically effective amount, or a prophylactically effective amount, of a combination of anticoccidial agents comprising a compound of Claim 1 and a second anticoccidial agent.
 - 30. The method of Claim 29 wherein said second anticoccidial agent is selected from the group consisting of amprolium, ethopabate, clopidol, meticlorpindol, decoquinate, dinitolmide, halofuginone, lasalocid, maduramicin, monensin, narasin, nicarbazin, chlortetracycline, oxytetracycline, robenidine, salinomycin, semduramicin, and diclazuril.
 - 31. The method of Claim 29 wherein said second anticoccidial agent is selected from the group consisting of amprolium, ethopabate, lasalocid, monensin, salinomycin, and diclazuril.

WQ 2005/060571 PCT/US2004/040617

32. A composition for controlling coccidiosis which comprises a compound of Claim 1 and a pharmaceutically acceptable carrier.

- 33. The composition of Claim 32 further comprising a second anticoccidial agent.
 - 34. The composition of Claim 33 wherein said second anticoccidial agent is selected from the group consisting of amprolium, ethopabate, clopidol, meticlorpindol, decoquinate, dinitolmide, halofuginone, lasalocid, maduramicin, monensin, narasin, nicarbazin, chlortetracycline, oxytetracycline, robenidine, salinomycin, semduramicin, and diclazuril.

10

15

- 35. The composition of Claim 33 wherein said second anticoccidial agent is selected from the group consisting of amprolium, ethopabate, lasalocid, monensin, salinomycin, and diclazuril.
 - 36. The composition of Claim 32 wherein said carrier is poultry feedstuff.
 - 37. The composition of Claim 36 further comprising a second coccidial agent.
- 38. The composition of Claim 37 wherein said second anticoccidial agent is selected from the group consisting of amprolium, ethopabate, clopidol, meticlorpindol, decoquinate, dinitolmide, halofuginone, lasalocid, maduramicin, monensin, narasin, nicarbazin, chlortetracycline, oxytetracycline, robenidine, salinomycin, semduramicin, and diclazuril.
- 25 39. The composition of Claim 37 wherein said second anticoccidial agent is selected from the group consisting of amprolium, ethopabate, lasalocid, monensin, salinomycin, and diclazuril.
 - 40. The composition of Claim 32 wherein said carrier is poultry feed premix.
 - 41. The composition of Claim 40 further comprising a second anticoccidial agent.
- 42. The composition of Claim 41 wherein said second anticoccidial agent is selected from the group consisting of amprolium, ethopabate, clopidol, meticlorpindol,

WO 2005/060571 PCT/US2004/040617

decoquinate, dinitolmide, halofuginone, lasalocid, maduramicin, monensin, narasin, nicarbazin, chlortetracycline, oxytetracycline, robenidine, salinomycin, semduramicin, and diclazuril.

- 43. A composition of Claim 41 wherein said second anticoccidial agent is selected from the group consisting of amprolium, ethopabate, lasalocid, monensin, salinomycin, and diclazuril.
 - 44. A composition for controlling malaria which comprises a compound of Claim 1 and a pharmaceutically acceptable carrier.
 - 45. A method for controlling malaria in a mammalian patient which comprises administering to said patient a therapeutically effective amount, or a prophylactically effective amount, of the compound of Claim 1.
- 15 46. A composition for controlling African trypanosomiasis which comprises a compound of Claim 1 and a pharmaceutically acceptable carrier.
 - 47. A method for controlling African trypanosomiasis in a mammalian patient which comprises administering to said patient a therapeutically effective amount, or a prophylactically effective amount, of a compound of Claim 1.
 - 48. A composition for controlling Chagas disease which comprises a compound of Claim 1 and a pharmaceutically acceptable carrier.
- 49. A method for controlling Chagas disease in a mammalian patient which comprises administering to said patient a therapeutically effective amount, or a prophylactically effective amount, of a compound of Claim 1.
- 50. A method for controlling toxoplasmosis in a mammalian patient which comprises administering to said patient a therapeutically effective amount, or a prophylactically effective amount, of a compound of Claim 1.
 - 51. A composition for controlling toxoplasmosis which comprises a compound of Claim 1 and a pharmaceutically acceptable carrier.

35

10

WO 2005/060571 PCT/US2004/040617

52. A method for controlling coccidiosis in poultry which comprises administering to said poultry a therapeutically effective amount, or a prophylactically effective amount, of a compound of Claim 21.

- 53. A method for controlling coccidiosis in poultry which comprises administering to said poultry a therapeutically effective amount, or a prophylactically effective amount, of a combination of anticoccidial agents comprising a compound of Claim 21 and a second anticoccidial agent.
- 10 54. A composition for controlling coccidiosis which comprises a compound of Claim 21 and a pharmaceutically acceptable carrier.
 - 55. The composition of Claim 54 further comprising a second anticoccidial agent.